Patient-derived cancer organoids are miniature tumors grown in the lab from donated tissue. Astudy由Dr. Matthew Weiss，诺斯韦尔癌症研究所的Feinstein医学研究所教授和副医师以及外科肿瘤学计划的主任，已经显示了如何从患者那里产生这些类器官 - 无论肿瘤阶段如何 - 并用于预测化学疗法功效。

捷克葡萄牙直播had the pleasure of talking to Weiss to learn more about patient-derived organoids and how these disease models could be used to develop personalized treatment strategies for pancreatic cancer.

凯特·罗宾逊（KR）：为什么类器官与个性化医学有关？

Matthew Weiss (MW):Everyone’s genetic and cellular makeup is unique. Patient-derived organoids are truly the definition of personalized care in the 21st century. The idea is that we take a patient’s cancer, grow it in the lab and test to see which type of chemotherapy is most effective for that individual tumor. Based on the genetic makeup of your own self, different drugs or combinations of drugs will work better in fighting the cancer. There is no one-size-fits-all care approach, particularly for cancer, and these organoids are a major step in treatment to help patients battling cancer to get better quicker, with fewer side effects, and get back to being cancer-free.

KR: How are organoids generated from patients?

MW:衍生患者的类器官的第一步是对体内生长的癌性肿瘤进行活检。我们要么通过外科手术或用针切除部分肿瘤。然后，我们服用这种癌性组织，将其带入实验室，并进行一系列测试，包括DNA测序。在类似培养皿的设置中，冷春港实验室的科学家会生长类器官，并开始测试哪种化学疗法最有效地杀死癌症。一旦我们了解了哪种药物或最好的药物结合，我们的目标就是将这种个性化治疗方法交付给该人。

KR: Why is the finding that organoids can be produced from patients with any stage of pancreatic cancer important?

MW:这是迄今为止报告的胰腺癌的最大的一系列患者衍生的器官。我们在收集的70％以上的组织样品中成功地产生了类器官的产生，并且患者是​​否已经接受了化学疗法并不重要。现在，该概念验证实验为将来的研究奠定了基础，这可能有一天会影响日常临床护理。

KR: How do you envision that your findings will impact the future of pancreatic cancer treatment?

MW:Current national guidelines favor the administration of systemic chemotherapy prior to surgery in most patients diagnosed with pancreatic cancer. However, currently we have no way of tailoring those therapies for an individual patient. My goal is that a patient will walk into my office and within a few weeks we will have them on personalized, highly-effective chemotherapy, so that we can increase our chances of surgically removing their tumor. With the potential organoids hold, we will be able to deliver better care quicker, with a personalized approach to optimize the likelihood of cure.

FACS医学博士Matthew Weiss与技术网络编辑助理Kate Robinson进行了交谈。捷克葡萄牙直播